Colorectal Cancer Survivorship

Colorectal cancer is the second leading cause of cancer-related death in the United States. In this lecture, Aki Ohinata, Physician Assistant in Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, says that the key to saving lives lies in detection and management. Ms. Ohinata specifically talks about the epidemiology and etiology of colorectal cancer and how to identify people who are at an increased risk of the disease. She describes how genetic mutations and family history play a role in colorectal cancer development.

Colorectal cancer is the second leading cause of cancer-related death in the United States. In this lecture, Aki Ohinata, Physician Assistant in Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, says that the key to saving lives lies in detection and management. Ms. Ohinata specifically talks about the epidemiology and etiology of colorectal cancer and how to identify people who are at an increased risk of the disease. She describes how genetic mutations and family history play a role in colorectal cancer development.

Surgery is the primary treatment for patients with localized colorectal cancer. In this lecture, Dr. Miguel Rodriguez-Bigas, Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center, describes and illustrates the types of bowel resection used for the treatment of colorectal cancer. Dr. Rodriguez-Bigas also discusses intestinal diversions and metastasectomy for the treatment of patients with advanced disease.

Surgery is the primary treatment for patients with localized colorectal cancer. In this lecture, Dr. Miguel Rodriguez-Bigas, Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center, describes and illustrates the types of bowel resection used for the treatment of colorectal cancer. Dr. Rodriguez-Bigas also discusses intestinal diversions and metastasectomy for the treatment of patients with advanced disease.

Radiotherapy can play an integral role in the treatment of colorectal cancer. In this lecture, Daniel Malatek, Physician Assistant in Radiation Oncology – GI Service at The University of Texas MD Anderson Cancer Center, describes the use of conventional radiotherapy, along with radiation seeds and proton therapy, in the treatment of colorectal cancer. Mr. Malatek shares how MD Anderson delivers the most advanced radiation therapies in treating colorectal cancer. He describes the foundational concepts in radiation therapy, possible side effects patients may face, and when it should be used in the treatment of colorectal cancer.

Radiotherapy can play an integral role in the treatment of colorectal cancer. In this lecture, Daniel Malatek, Physician Assistant in Radiation Oncology – GI Service at The University of Texas MD Anderson Cancer Center, describes the use of conventional radiotherapy, along with radiation seeds and proton therapy, in the treatment of colorectal cancer. Mr. Malatek shares how MD Anderson delivers the most advanced radiation therapies in treating colorectal cancer. He describes the foundational concepts in radiation therapy, possible side effects patients may face, and when it should be used in the treatment of colorectal cancer.

Combined targeted therapy with chemotherapy can improve overall survival for patients with metastatic disease. In this lecture, Dr. David Fogelman, Assistant Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses chemotherapy agents currently utilized in the treatment of colorectal cancer. Dr. Fogelman explains the role of chemotherapy in the neoadjuvant, adjuvant, and metastatic settings of colorectal cancer.

Combined targeted therapy with chemotherapy can improve overall survival for patients with metastatic disease. In this lecture, Dr. David Fogelman, Assistant Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses chemotherapy agents currently utilized in the treatment of colorectal cancer. Dr. Fogelman explains the role of chemotherapy in the neoadjuvant, adjuvant, and metastatic settings of colorectal cancer.

Pain, diminishing body image, bowel issues, and sexual dysfunction. Colleen Reeves, Advanced Practice Nurse in Surgical Oncology at The University of Texas MD Anderson Cancer Center, says these are just a few of the challenges colorectal cancer survivors may face after surgery. In this lecture for health professionals, Ms. Reeves talks about how to differentiate between the acute and late effects of colorectal surgery. She discusses the complications that may arise from the late effects of surgery and offers insight into how to diagnose and manage the different types of late effects that colorectal cancer survivors may face.

Pain, diminishing body image, bowel issues, and sexual dysfunction. Colleen Reeves, Advanced Practice Nurse in Surgical Oncology at The University of Texas MD Anderson Cancer Center, says these are just a few of the challenges colorectal cancer survivors may face after surgery. In this lecture for health professionals, Ms. Reeves talks about how to differentiate between the acute and late effects of colorectal surgery. She discusses the complications that may arise from the late effects of surgery and offers insight into how to diagnose and manage the different types of late effects that colorectal cancer survivors may face.

Lymphedema, bone fractures, sterility, fatigue, and chronic diarrhea—these are just a few of the late side effects patients (≤ 10%) may suffer following radiation therapy for colorectal cancer. In this lecture, Daniel Malatek, Physician Assistant in the Radiation Oncology Gastrointestinal Service at The University of Texas MD Anderson Cancer Center, differentiates acute side effects from late side effects, describes common and uncommon late side effects, and suggests how to best treat and manage late side effects.

Lymphedema, bone fractures, sterility, fatigue, and chronic diarrhea—these are just a few of the late side effects patients (≤ 10%) may suffer following radiation therapy for colorectal cancer. In this lecture, Daniel Malatek, Physician Assistant in the Radiation Oncology Gastrointestinal Service at The University of Texas MD Anderson Cancer Center, differentiates acute side effects from late side effects, describes common and uncommon late side effects, and suggests how to best treat and manage late side effects.

Many colorectal cancer patients develop some late effects of chemotherapy following treatment. They could take weeks, months, even years to develop, but patients can experience fatigue, cognitive dysfunction known as "chemobrain," reproduction or sexuality issues, osteoporosis, and even cataracts. In this lecture, Dr. Alexandria Phan, Associate Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, describes how to recognize general long-term or late effects of chemotherapy agents.

Many colorectal cancer patients develop some late effects of chemotherapy following treatment. They could take weeks, months, even years to develop, but patients can experience fatigue, cognitive dysfunction known as "chemobrain," reproduction or sexuality issues, osteoporosis, and even cataracts. In this lecture, Dr. Alexandria Phan, Associate Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, describes how to recognize general long-term or late effects of chemotherapy agents.

The cancer may be gone, but the fear remains. Colorectal cancer survivors ask themselves, "Will the cancer come back or develop somewhere else?" These survivors' health care professionals want to make sure that they are providing appropriate surveillance. Maura Polansky, Physician Assistant in the Department of Gastrointestinal Medical Oncology and Director of Physician Assistant Education at The University of Texas MD Anderson Cancer Center, takes a look at data that can help physicians plan the most effective long-term follow-up care for colorectal cancer survivors.

The cancer may be gone, but the fear remains. Colorectal cancer survivors ask themselves, "Will the cancer come back or develop somewhere else?" These survivors' health care professionals want to make sure that they are providing appropriate surveillance. Maura Polansky, Physician Assistant in the Department of Gastrointestinal Medical Oncology and Director of Physician Assistant Education at The University of Texas MD Anderson Cancer Center, takes a look at data that can help physicians plan the most effective long-term follow-up care for colorectal cancer survivors.

Colorectal cancer survivors, particularly women, are at an increased risk of developing a second primary cancer. In her lecture, Dr. Therese Bevers, Professor of Clinical Cancer Prevention and Medical Director of the Cancer Prevention Center at The University of Texas MD Anderson Cancer Center, defines second primary cancers, identifies risk of second primary cancers after colorectal cancer, and discusses why second primary cancers occur more frequently in women than in men.

Colorectal cancer survivors, particularly women, are at an increased risk of developing a second primary cancer. In her lecture, Dr. Therese Bevers, Professor of Clinical Cancer Prevention and Medical Director of the Cancer Prevention Center at The University of Texas MD Anderson Cancer Center, defines second primary cancers, identifies risk of second primary cancers after colorectal cancer, and discusses why second primary cancers occur more frequently in women than in men.

When managing colorectal cancer risk, it's important to start with family history. In his lecture, Dr. Patrick Lynch, Professor in the Department of Gastroenterology, Hepatology, and Nutrition at The University of Texas MD Anderson Cancer Center, describes how to recommend evidence-based enhanced colorectal cancer screening for patients with hereditary nonpolyposis colorectal cancer (HNPCC).

When managing colorectal cancer risk, it's important to start with family history. In his lecture, Dr. Patrick Lynch, Professor in the Department of Gastroenterology, Hepatology, and Nutrition at The University of Texas MD Anderson Cancer Center, describes how to recommend evidence-based enhanced colorectal cancer screening for patients with hereditary nonpolyposis colorectal cancer (HNPCC).

The origins of colorectal cancer are multifactorial. Some cancers progress from premalignant polyps; others may be associated with a history of inflammatory bowel disease. Other colorectal cancers are thought to be familial. The two most common inherited syndromes linked with colorectal cancer are familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC). In this lecture, Dr. Patrick Lynch, Professor in the Department of Gastroenterology, Hepatology, and Nutrition at The University of Texas MD Anderson Cancer Center, describes how to recognize distinctions between the two syndromes.

The origins of colorectal cancer are multifactorial. Some cancers progress from premalignant polyps; others may be associated with a history of inflammatory bowel disease. Other colorectal cancers are thought to be familial. The two most common inherited syndromes linked with colorectal cancer are familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC). In this lecture, Dr. Patrick Lynch, Professor in the Department of Gastroenterology, Hepatology, and Nutrition at The University of Texas MD Anderson Cancer Center, describes how to recognize distinctions between the two syndromes.